SCHEDULE: 3i, LP Updates Beneficial Ownership in CNBX Pharmaceuticals

3i, LP and associated entities report a 9.9% beneficial ownership stake in CNBX Pharmaceuticals following recent share issuances.

Summary

• 3i, LP, 3i Management LLC, and Maier Joshua Tarlow filed an amendment to their Schedule 13G regarding their holdings in CNBX Pharmaceuticals Inc.
• The reporting persons beneficially own 124,946,375 shares of common stock.
• This ownership represents 9.9% of the total outstanding common stock of the issuer.
• The holdings consist of 100,000,000 shares held directly and 24,946,375 shares issuable upon conversion of a senior secured convertible note.
• The conversion of the note is subject to a 9.99% beneficial ownership limitation (the Blocker).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory update confirming the current ownership status of a major investor.

Positives

• The reporting persons maintain a significant equity position, signaling continued investment interest in the company.

Negatives

• The presence of a 9.99% ownership blocker indicates a strategic limit on the reporting person's ability to increase their stake or influence control beyond current levels.

Risks

• The conversion of the senior secured convertible note is subject to a 9.99% beneficial ownership limitation, which may restrict the liquidity or timing of share acquisition.
• The company's high number of outstanding shares (1,225,768,095) may lead to significant dilution for existing shareholders.

Future Outlook

The filing does not provide a forward-looking business outlook, as it is a regulatory disclosure regarding beneficial ownership.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional investor reporting requirements for small-cap pharmaceutical companies, where convertible debt is frequently used as a financing mechanism.

Comparison to Industry Standards

• The use of a 9.99% ownership blocker is a standard protective provision in institutional investment agreements to avoid triggering change-of-control clauses or regulatory thresholds.

Stakeholder Impact

• Shareholders should be aware of the potential for future dilution if the convertible note is exercised, subject to the 9.99% blocker.

Next Steps

• Continued monitoring of the 9.99% ownership blocker regarding potential future conversions of the note.

Key Dates

Keywords

CNBX Pharmaceuticals, 3i LP, Schedule 13G, Beneficial Ownership, Convertible Note, Equity Investment